Rachel Sacks-Davis, Daniela K van Santen, Anders Boyd, Jim Young, Ashleigh Stewart, Joseph S Doyle, Andri Rauch, Catrina Mugglin, Marina Klein, Marc van der Valk, Colette Smit, Inmaculada Jarrin, Juan Berenguer, Karine Lacombe, Maria-Bernarda Requena, Linda Wittkop, Olivier Leleux, Fabrice Bonnet, Dominique Salmon, Gail V Matthews, Rebecca Guy, Natasha K Martin, Tim Spelman, Maria Prins, Mark Stoove, Margaret Hellard
BACKGROUND: Reinfection after successful treatment with direct-acting antivirals is hypothesised to undermine efforts to eliminate hepatitis C virus (HCV) infection among people with HIV. We aimed to assess changes in incidence of HCV reinfection among people with HIV following the introduction of direct-acting antivirals, and the proportion of all incident cases attributable to reinfection. METHODS: We pooled individual-level data on HCV reinfection in people with HIV after spontaneous or treatment-induced clearance of HCV from six cohorts contributing data to the International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC) in Australia, Canada, France, the Netherlands, Spain, and Switzerland between Jan 1, 2010, and Dec 31, 2019...
January 12, 2024: Lancet HIV